Good Samaritan Hospital Department of Anesthesia Perioperative Guidelines

NPO GUIDELINES*

Clear liquids: > 2 hours

Breast Milk: > 4 hours

Light meal (toast): > 6 hours

Heavy meal (meat, fried or fatty food): > 8 hours

* For healthy patients with normal gastric emptying

| PREOPERATIVE TESTING: STEP 1* | | | | |
|--|-----------------|---------|-----|--|
| EXPECTED BLOOD LOSS | CBC | T&S | T&C | |
| EBL <100 | | | | |
| EBL 100-500 mL | Х | 1 | | |
| EBL >500 mL | Х | Х | 1 | |
| * Studies valid for 6 months unless there has been a change in medical history | | | | |
| 1) Consider for patients with significant medical problems, anemia or previo | ous blood trans | sfusion | | |

| PREOPERATIVE TESTING: STEP 2* | | | | | | | | | | | |
|---|---------------------|--------------------|-------------------|-------------------|-------------------|--------------------|--------------------|--------------------|-------------|------|----------|
| ALL SURGERIES | CBC | Glucose | Chem 7 | LFTs | Coags | Preg Test | ECG | Echo | CXR | PFTs | Consults |
| Female with childbearing potential | | | | | | OFFER | | | | | |
| Active cardiac condition (<i>No Elective Surgery. Emergency surgery only.</i> | v | | × × | X | × | | X | × × | X | | × × |
| Requires Anesthesia consult) | X | | X | X | X | | X | X | X | | X |
| LOW RISK SURGERY (Endoscopic procedures, Ophthalmic surgery, Superfici | ial procedures, | Minor Proced | ures) | | | | | | | | |
| | No Routine T | esting Necessa | ry | | | | | | | | |
| INTERMEDIATE RISK SURGERY (Nonambulatory Neuro, ENT, Thoracic, Intra | peritoneal, Gyi | necologic, Urol | logic, Orthope | dic surgery) O | R HIGH RISK S | URGERY (Vasci | ular) | | | | |
| Cardiac disease | | | | | | | | | | | |
| Cardiac disease with exercise tolerance > 4 METs | | | | | | | 3 | | | | |
| Cardiac disease with exercise tolerance < 4 METs | х | | | | | | х | 2 | | | |
| Stable coronary artery disease or congestive heart failure | | | | | | | х | | | | 1 |
| Left Ventricular Dysfunction or ≥ moderate valvular disease | х | | Х | | | | х | х | | | |
| High risk murmur | | | | | | | х | 2 | | | |
| Pulmonary disease | | | | | | | | | | | |
| Stable respiratory disease with exercise tolerance > 4 METs | | | | | | | 3 | | | | |
| Stable respiratory disease with exercise tolerance < 4 METs | х | | | | | | х | 2 | | | |
| Unstable or severe, uncharacterized respiratory disease | х | | х | | | | х | х | х | +/- | х |
| Other disease | | | | | | | | | | | |
| Cerebrovascular disease | | | | | | | х | | | | 1 |
| Diabetes | | х | +/- | | | | х | | | | 1 |
| Renal insufficiency | х | | х | | | | х | | | | 1 |
| Liver disease | | | х | х | х | | 3 | | | | |
| Hematologic disorders | х | | | | | | 3 | | | | |
| Coagulopathies | х | | | | х | | 3 | | | | |
| Malignancy | +/- | | | | | | 3 | | | | |
| Current drug therapy | | | | | | | | | | | |
| Diuretics | | | Х | | | | | | | | |
| Coumadin | | | | | Х | | | | | | |
| Digoxin | | | | | | | х | | | | |
| Chemotherapy (Within last 3 months) | X | | | | | | | | | | |
| * Studies valid for 6 months unless there has been a change in medical history | | | | | | | | | | | |
| 1) If it will change management, consider consult and/or testing if patient has exercise | e tolerance < 4 M | ETs and at least 1 | of 5 risk factors | including ischer | nic heart disease | e, CHF, cerebrova | scular disease in | cluding TIA, IDD | М, | | |
| and renal insufficiency with Cr >2.0 | | | | | | | | | | | |
| 2) Consider echo if it will change management for patients with cardiac or pulmonary disease and exercise tolerance < 4 METs or patients with high risk murmurs including diastolic, continuous, holosystolic, late systolic, | | | | | | | | | | | |
| ≥ grade 3/6, murmurs with an ejection click or radiation to neck or back, murmurs of known valvular disease in a patient with a change in symptoms, or murmurs in a patient with cardiac disease or abnormal ECG or CXR | | | | | | | | | | | |
| 3) ECG indicated for patients scheduled for high risk surgery but not intermediate risk s | surgery | | | | | | | | | | |
| METs: Metabolic equivalent of tasks. 4 METs is roughly equivalent to climbing a flight o | of stairs, walking | up a hill or walk | ing on flat grour | nd at 3-4 mph | | | | | | | |
| Emergency surgery: Surgery necessary given risk to life or limb | | | | | | | | | | | |
| Active cardiac condition: 1) Unstable coronary syndromes: Unstable or severe angina, | myocardial infa | rction within las | t 30d; 2) Decomp | ensated heart fo | ailure: NYHA clas | ss IV, worsening o | r new-onset hea | rt failure; | | | |
| 3) Significant arrhythmias: High-grade atrioventricular block, Mobitz II atrioven | ntricular block, tl | hird-degree atrio | ventricular hear | t block, symptoi | matic ventricula | r arrhythmias in | cluding atrial fib | orillation with ur | ncontrolled | | |
| ventricular rate (HR > 100 beats per minute at rest), symptomatic bradycardia, n | newly recognized | ventricular tach | ycardia; 4) Sever | re valvular disea | se: Severe aortic | stenosis (mean p | ressure gradient | >40 mmHg, | | | |
| aortic valve area < 1.0 cm2, or symptomatic), symptomatic mitral stenosis (progressive dyspneg on exertion, exertional presyncope, or HF) | | | | | | | | | | | |

| DAY OF SURGERY DRUG MANAGEMENT | CONTINUE | HOLD |
|--|----------|------|
| Beta Blockers | Х | |
| Statins | Х | |
| Calcium channel blockers | X | |
| ACEi and ARBs | | Х |
| Alpha2 agonists (e.g., Clonidine) | X | |
| Diuretics | | Х |
| Insulin | 1 | |
| Oral diabetes medications | | 2 |
| PPIs and H2-blockers | Х | |
| NSAIDs | | Х |
| Aspirin | 2 | |
| Clopidogrel (Plavix) and Effient (Prasugrel) | | 2 |
| Anticoagulants (e.g., Coumadin, Pradaxa, Xarelto, Eliquis) | | 2 |
| Anti-Rejection medications | X | |
| Opiates | Х | |
| Antidepressants (except MAOi) | X | |
| Dietary supplements | | Х |
| 1) Generally patient should take 80% of their long acting basal insulin prior to surgery | | |
| 2) Consult anesthesiologist | | |



MI: myocardial infarction; PCI: percutaneous coronary intervention; BMS: bare metal stent; DES: drug eluting stent; CAD: coronary artery disease; CHF: congestive heart failure; CVD: cerebrovascular disease; IDDM: insulin-dependent diabetes mellitus; CRI: chronic renal insufficiency with creatinine > 2.0

1) Risk of thrombosis is generally greater than risk of surgical bleeding and aspirin therapy should be continued. Consider stopping aspirin if multidisciplinary discussion deems risk of surgical bleeding to be greater than risk of thrombosis (e.g. select neurosurgery procedures)

2) Risk of thrombosis is generally much greater than risk of surgical bleeding and antiplatelet therapy should be continued. If multidisciplinary discussion deems risk of surgical bleeding to be greater than risk of thrombosis (e.g. select neurosurgery procedures) continue aspirin and stop plavix.

3) Ideally delay surgery until dual antiplatelet therapy is complete in patients with cardiac stents (12 months following any DES; 12 months following BMS with STEMI). After this time and in all others, continue aspirin and stop plavix. If high risk for atherosclerotic event (previous thrombosis, L main stent, multivessel stenting, stent in only remaining coronary artery or graft conduit) undergoing low bleeding risk procedure, consider continuing both aspirin and plavix.

| Anticoagulant | Mechanism of Action | Last Dose Prior to Surgery | Comments |
|------------------------|---|--|--|
| | Vitamin K antagonist (inhibition of II, | | Monitor INR; Reversal with Vitamin K, |
| Warfarin (Coumadin) | VII, IX, X) | Generally 5 days | FFP or 4 factor PCCs |
| | Antithrombin activation (inhibition of | | |
| Unfractionated heparin | lla, IXa, Xa, Xla, Xlla) | IV 2-6 hours | Monitor PTT; Reversal with protamine |
| | Antithrombin activation (inhibition of | | Possible to monitor anti-Xa level; Partial |
| LMWH (Lovenox) | Xa>>IIa) | 24 hours | reversal with protamine |
| | Antithrombin activation (inhibition of | | No reversal agent, consider factor VIIa |
| Fondaparinux (Arixtra) | Xa) | 36-48 hours | in cases of major bleeding |
| | | | PTT to rule out residual effect; Praxbind |
| | | 1-2 days with CrCl >50, 3-5 days with | for reversal. Can be removed with |
| Dabigatran (Pradaxa) | Direct thrombin inhibitor | CrCl <50 | dialysis |
| | | 1 day with normal CrCl, 2 days with CrCl | PT or anti-Xa to rule out residual effect; |
| | | 60-90, 3 days with CrCl 30-59, 4 days | No reversal agent, consider PCCs for |
| Rivaroxaban (Xarelto) | Direct Xa inhibitor | with CrCl 15-29 | major bleeding |
| | | | Anti-Xa to rule out residual effect; No |
| | | 2 days with CrCl >60, 3 days with CrCl | reversal agent, consider 4 factor PCCs |
| Apixaban (Eliquis) | Direct Xa inhibitor | 50-59, 5 days with CrCl 20-49 | for major bleeding |

Perioperative Diabetic Medication Management

Oral hypoglycemic agents

| Agent0000 | Day before admission | Surgery in morning | Surgery in afternoon | If an insulin infusion is started |
|-------------------|-------------------------|--|--|---|
| Meglitinides | Take as normal | Omit morning dose | Give morning dose if eating | Stop until eating and drinking normally |
| Sulphonylurea | Take as normal | Omit morning dose | Omit morning dose | Stop until eating and drinking normally |
| SGLT-2 inhibitors | No dose change | Reduce morning dose by 50% Check BG on admission Retake evening dose if eating | Reduce morning dose by 50% Check BG on admission Retake evening dose if eating | Stop until eating and drinking normally |
| Acarbose | Take as normal | Omit morning dose | Give morning dose if eating | Stop until eating and drinking normally |
| DPP-IV inhibitors | Take as normal | Take as normal | Take as normal | Take as normal |
| GLP-1 analogues | Take as normal | Take as normal | Take as normal | Stop until eating and drinking normally |
| Metfomin | Take as normal | Take as normal | Take as normal | Stop until eating and drinking normally |
| Pioglitazone | Take as normal | Take as normal | Take as normal | Stop until eating and drinking normally |

Metformin should be stopped if patient is receiving contrast medium or estimated GFR > 60cc/min

Ref: Membership of the Working Party, Barker, P., Creasey, P. E., Dhatariya, K., Levy, N., Lipp, A., Nathanson, M. H., Penfold, N., Watson, B. and Woodcock, T. (2015), Peri-operative management of the surgical patient with diabetes 2015. Anaesthesia, 70: 1427–1440. doi: 10.1111/anae.13233

Perioperative Diabetic Medication Management

Long acting insulin (Lantus (glargine), levemir (detemir), tresiba, insulatard, Insuman)

| Taken | Day before admission | Surgery in the morning | Surgery in the afternoon | If an insulin infusion is started |
|------------|----------------------|--------------------------------------|--------------------------------------|-----------------------------------|
| QD evening | Reduce dose by 20% | Check BG on admission | Check blood glucose on admission | Continue at 80% of usual dose |
| QD morning | Reduce dose by 20% | Reduce dose check BG on admission | Reduce dose check BG on admission | Continue at 80% of usual dose. |

Biphasic or mixed insulin (Novomix30, humulin (NPH), Humalog mix, insuman comb, levemir, Lantus)

| Taken | Day before admission | Surgery in the morning | Surgery in the afternoon | If an insulin infusion is started |
|-------|----------------------|--|--|--|
| BID | No change in dose | Reduce morning dose by 50% Check BG on admission Restart normal dose at night if eating. | Reduce morning dose by 50% Check BG on admission Restart normal dose at night if eating. | Hold subcutaneous insulin Restart when patient is eating. |

Short and intermediate acting insulin (Novorapid (aspart), humulin S, apidra, humulin)

| Taken | Day before admission | Surgery in the morning | Surgery in the afternoon | If an insulin infusion is started |
|-------|----------------------|---|---|--|
| BID | No change in dose | Calculate total morning dose and give 50% of intermediate-acting insulin Check BG on admission Restart normal dose at night if eating. | Calculate total morning dose and give 50% of intermediate-acting insulin Check BG on admission Restart normal dose at night if eating. | Hold subcutaneous insulin Restart when patient is eating. |

Basal/bolus regimens (long-acting insulin with short acting insulin for meals)

| Taken | Day before admission | Surgery in the morning | Surgery in the afternoon | If an insulin infusion is started |
|------------------------------|----------------------|--|---|--|
| 3-5 injections per day | No change in dose | Normal basal injection Omit morning and lunch short-acting dose Keep basal rate Check BG on admission For premixed insulin- halve morning dose, and omit lunchtime dose | Give normal morning insulin dose Omit lunchtime dose Check BG on admission | Stop short acting insulin Continue long acting insulin dose at 80% |